How much has the cancer R&D frenzy translated into drug approvals? A lot
When the FDA formally launched the Oncology Center of Excellence in 2017, it marked the culmination of years of encouraging and facilitating speedy cancer drug development. And according to a new study, the effects are translating to new drug approvals.
Tufts’s renowned Center for the Study of Drug Development has dedicated its latest bi-monthly analysis report to quantifying the surge of new oncology products from 2010 to 2018. Researchers found that cancer drugs accounted for 27% of all new drug approvals in the US, a steep spike from 4% in the 1980s.
This dramatic growth outpaced that of anti-infectives, cardiovascular and CNS drugs, they added.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 66,100+ biopharma pros reading Endpoints daily — and it's free.